Penumbra, Inc. Stock price

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 02:35:52 2024-02-21 pm EST 5-day change 1st Jan Change
257.3 USD -4.22% Intraday chart for Penumbra, Inc. -4.22% +2.16%
Sales 2023 * 1.06B Sales 2024 * 1.27B Capitalization 10.37B
Net income 2023 * 71M Net income 2024 * 109M EV / Sales 2023 * 9.64 x
Net cash position 2023 * 140M Net cash position 2024 * 188M EV / Sales 2024 * 8.04 x
P/E ratio 2023 *
145 x
P/E ratio 2024 *
96.1 x
Employees 3,900
Yield 2023 *
-
Yield 2024 *
-
Free-Float 96.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.72%
1 week+1.46%
Current month+6.51%
1 month+7.31%
3 months+14.08%
6 months+6.92%
Current year+6.79%
More quotes
1 week
263.58
Extreme 263.575
277.34
1 month
241.87
Extreme 241.87
277.34
Current year
225.85
Extreme 225.85
277.34
1 year
180.93
Extreme 180.93
348.67
3 years
114.87
Extreme 114.865
348.67
5 years
114.87
Extreme 114.865
348.67
10 years
35.32
Extreme 35.315
348.67
More quotes
Managers TitleAgeSince
Founder 62 04-06-20
Chief Executive Officer 62 04-06-20
Director of Finance/CFO 52 19-12-01
Members of the board TitleAgeSince
Director/Board Member 60 17-01-12
Director/Board Member 57 15-03-31
Chief Executive Officer 62 04-06-20
More insiders
Date Price Change Volume
24-02-21 257 -4.33% 215 194
24-02-20 268.6 -0.72% 246,965
24-02-16 270.6 -0.95% 225,551
24-02-15 273.2 +1.80% 237,699
24-02-14 268.3 +1.34% 178,353

Delayed Quote Nyse, February 20, 2024 at 04:00 pm EST

More quotes
Penumbra, Inc. is a global healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. It has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The Company's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The Company sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
268.6 USD
Average target price
284 USD
Spread / Average Target
+5.73%
Consensus
1st Jan change Capi.
+6.79% 10 367 M $
+12.18% 6 948 M $
-7.31% 5 497 M $
+0.54% 5 199 M $
+5.23% 5 007 M $
+10.68% 3 978 M $
-10.49% 3 347 M $
+1.36% 2 082 M $
+8.09% 1 952 M $
+5.96% 1 691 M $
Medical Equipment
  1. Stock
  2. Equities
  3. Stock Penumbra, Inc. - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer